Fecol

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fecol

Quick Facts

Property Description
Active Ingredients Acetaminophen, Chlorphenamine Maleate, Phenylephrine HCl, Salicylamide
Form Solid Oral Form (Tablet/Capsule)
Pharmacological Class Multi-component Analgesic, Antipyretic, Antihistamine, Decongestant
Common Purpose Symptomatic relief of cold, flu, and allergy discomfort
Origin/Type Synthetic Fixed-Dose Combination (FDC)

What Type of Drug is Fecol and What Is Its Composition?

Fecol is a fixed-dose combination (FDC) pharmaceutical preparation, clinically recognized as an Upper Respiratory Combination. This synthetic medicine is typically supplied in solid oral form (such as a tablet or capsule) for oral administration, designed to provide concurrent relief for multiple symptoms.

The preparation is defined by its complex composition, including four distinct active ingredients by International Nonproprietary Name (INN): Acetaminophen, Chlorphenamine Maleate, Phenylephrine Hydrochloride, and Salicylamide. The combination of these four distinct classes of agents is intended to provide overall relief compared to monotherapies. This confirms that the drug’s composition helps ease various discomforts more effectively than single-ingredient treatments.


What is the General Purpose of Fecol?

The general purpose of Fecol is to provide comprehensive, systematic, symptomatic relief for the combined discomforts associated with the common cold, the flu, and seasonal allergies. Its primary aim is to manage the typical cluster of symptoms that often overlap during these minor illnesses, promoting a better state of comfort.

The multi-action formulation means Fecol is designed to simultaneously help manage pain, reduce fever, control allergy symptoms (due to the H1 blocking action of Chlorphenamine Maleate), and ease nasal congestion. Phenylephrine is a decongestant that acts on specific receptors to shrink swollen nasal tissue. This mechanism helps reduce congestion and makes breathing easier. As an FDC, its unique aspect is offering this broad, systemic action, typically used when a patient presents with a headache alongside a stuffy nose and sneezing.

Regulatory References

  1. Phenylephrine: MedlinePlus Drug Information

What side effects are possible with Fecol?

Possible Side Effects and Safety Information

The safety profile for Fecol, a product derived from the fecal microbiota (similar to Fecal Microbiota for Transplantation, or FMT), includes common, generally mild adverse reactions as well as rare, serious risks explicitly documented by regulatory agencies.

Adverse Reactions

Adverse reactions are officially categorized by System Organ Class (SOC) and frequency, adhering to standardized regulatory frameworks (e.g., EMA/ICH frequency bands). The most common and typically transient adverse events include gastrointestinal symptoms such as:

  • Abdominal discomfort or pain
  • Bloating and flatulence
  • Nausea and diarrhea (or exacerbation of existing diarrhea)

These effects are generally mild to moderate and often resolve without specific intervention. Serious adverse events (SAE) are rare but include severe infections.

Clinically Significant and Serious Safety Risks

Regulatory warnings emphasize the potential risk of transmission of pathogenic organisms, which may result in serious or life-threatening infections, particularly in immunocompromised patients or those with underlying chronic medical conditions. Documented infections include the transmission of multi-drug resistant organisms (MDROs), such as Extended-Spectrum Beta-Lactamase (ESBL)-producing E. coli, and other pathogenic bacteria like Shigatoxin-producing Escherichia coli (STEC) and Enteropathogenic E. coli (EPEC).

This risk requires the highest level of vigilance in donor screening and product testing. Regulatory safety monitoring focuses on tracking all suspected adverse events, particularly serious infections, to continuously evaluate and manage the risk profile.

Overdose and Emergency Response

The regulatory guidance for Fecol overdose is defined by the combined toxicity profile of its active components, primarily focusing on potential for severe, life-threatening outcomes. Because initial symptoms of overdose can be delayed or mimic cold/flu manifestations, quick medical attention is critical for all individuals, even if no severe signs are immediately apparent. In case of suspected overdose, individuals must contact a Poison Control Center or get medical help right away, as officially documented.

An overdose may present with clinical manifestations such as severe drowsiness, confusion, hallucinations, and agitation, alongside potential cardiovascular effects including severe hypertension and rapid or uneven heart rate. The most critical documented complication is severe liver damage (hepatotoxicity), which can progress to liver failure and death. Other severe outcomes documented in official sources include seizures, cardiovascular collapse, and severe skin reactions.

Management procedures officially described in regulatory documents include the immediate use of the antidote N-acetylcysteine (NAC) for the acetaminophen component, in addition to symptomatic and supportive care. Hospital monitoring requirements include observation of vital signs, cardiac monitoring (ECG), and obtaining blood tests, such as serum acetaminophen concentration and liver function tests, to guide treatment. Population-specific notes confirm that children are at a higher risk for severe reactions.

Therapeutic Uses of Fecol

What Fecol Treats: Main Uses and Benefits

Fecol is applied in addressing symptomatic discomfort associated with acute or episodic changes, such as the common cold, influenza, and seasonal allergic rhinitis. It supports symptomatic relief across key domains where short-term symptomatic assistance is needed. Such fixed-dose combinations are commonly used in settings where additional symptomatic support is required.

The medication helps manage a cluster of common manifestations, including headache and fever, nasal congestion, runny nose, sneezing, and body aches. It is typically applied in addressing situations where these symptoms interfere with daily functioning and supports the patient during difficult episodes.

“The product is commonly used across conditions presenting with acute episodes and relevant in contexts involving heightened systemic burden.”


Quick Fact: Relief for Multiple Acute Symptoms

Domain Key Symptom Focus Therapeutic Benefit
Systemic Headache, Fever, Body Aches Contributes to improved day-to-day comfort
Nasal Stuffy Nose, Sinus Pressure May assist with maintaining functional stability
Irritative Sneezing, Runny Nose, Itchy Eyes Helps manage these disruptive manifestations

Regulatory References

  1. DailyMed: Acetaminophen, Chlorpheniramine, Phenylephrine, Dextromethorphan label

Eligibility and Restrictions for Use

Who Can and Cannot Use Fecol?

This section outlines Fecol’s official population eligibility and non-eligibility status, based strictly on governmental regulatory documents.


Eligibility Scope

Populations for whom use is allowed (as stated in label): Use is permitted for adults and adolescents 12 years of age and older.

Populations for whom use is not recommended (if applicable): Use is not recommended for women who are breastfeeding or during the first and second trimesters of pregnancy.

Populations for whom use is contraindicated: Patients with severe uncontrolled hypertension, severe coronary artery disease, or phaeochromocytoma must not use Fecol. It is also contraindicated in patients with severe hepatic impairment, narrow-angle glaucoma, or those taking Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of stopping MAOIs.

Age-related eligibility rules: Fecol is contraindicated in children under 12 years. Older adults may use the medicine but require official caution.

Condition-specific eligibility rules (Conditional Use): Conditional use is specified for patients with mild to moderate hepatic impairment, severe renal impairment, diabetes mellitus, hyperthyroidism, or specific respiratory conditions like asthma or COPD.

Pregnancy and lactation eligibility status (if explicitly documented): Use is contraindicated in the third trimester of pregnancy.


Eligibility Classifications (High-Level)

Eligibility severity classification (as defined in official documents): Contraindicated, Not Recommended, Use with Caution.

Regulatory basis (EMA / FDA / etc.): FDA DailyMed, EMA SmPC, and national regulatory bodies define the criteria.

Eligibility-context constraints (as defined in official documents): Restrictions are primarily driven by the risks associated with the combined sympathomimetic, anticholinergic, and hepatic/gastrointestinal components.


Resulting Eligibility Structure

Official eligibility statements:

  • Fecol is contraindicated in patients with severe hepatic impairment.
  • The medicine is contraindicated in patients receiving MAOIs.
  • The use of Fecol is contraindicated in children under 12 years.
  • Use is not recommended during the third trimester of pregnancy.
  • Use is specified as with caution in older adults.

Connection to the overall eligibility profile (2–4 sentences): The official eligibility profile defines who can and cannot use Fecol by establishing firm boundaries based on age and pre-existing medical status. Regulatory documents formally prohibit use in pediatric patients under 12 and in adults with specific severe cardiovascular or hepatic conditions. They also mandate special caution or state a "not recommended" status for individuals with chronic metabolic disorders or during pregnancy and lactation.

What should I know about interactions with other medicines?

Contraindicated Combinations and Mandatory Timing

Co-administration of Fecol is strictly prohibited with certain medicines to manage life-threatening risks. These prohibitions apply to Monoamine Oxidase Inhibitors (MAOIs), Ergot Alkaloids, and all other medicinal products containing Acetaminophen. Specifically, a mandatory 14-day separation window is required after discontinuation of MAOI therapy before Fecol can be initiated, addressing the potential for severe hypertensive crisis.

Documented Pharmacodynamic Effects

Interactions concerning pharmacodynamic reinforcement are documented for multiple substance classes. The combination with CNS depressants (such as sedatives or tranquilizers) or alcohol is officially listed as causing additive CNS depression, leading to increased drowsiness. Similarly, co-use with other sympathomimetic agents may lead to an increased risk of additive cardiovascular effects.

Alteration of Drug Exposure

The levels of Fecol’s components may be modified by co-administered agents. The absorption rate of Acetaminophen is officially documented to be increased by Metoclopromide or Domperidone and reduced by Colestyramine. This fixed-dose combination may also lead to an enhanced anticoagulant effect when co-administered with Warfarin. Furthermore, the presence of enzyme-inducing drugs may increase the documented hazard of hepatic damage.

️ Alcohol and Population-Specific Risk

Alcohol consumption is mandated to be avoided with this product. This strict avoidance addresses the significant and officially documented risk of severe liver damage. Regulatory warnings note that patients with non-cirrhotic alcoholic liver disease are a population facing a greater hazard of Acetaminophen-related hepatotoxicity when combined with alcohol.

Mechanism of Action

Modulation of Central and Peripheral Nociception

The effects on thermal regulation and nociception engage the Cyclooxygenase (COX) enzyme system centrally and peripherally. Acetaminophen modulates COX activity primarily within the brain, reducing Prostaglandin E2 (PGE2) synthesis in the hypothalamus, resulting in the adjustment of the elevated hypothalamic thermal set-point. Salicylamide supports this by inhibiting COX activity in peripheral tissues, thereby suppressing nociceptive signal transduction outside the central nervous system.


Dual Mechanism for Mucosal Regulation

The modulation of mucosal volume and fluid dynamics involves two complementary mechanisms. The molecule Phenylephrine acts as an agonist on Alpha-1 (alpha1) Adrenergic Receptors in the nasal vasculature, causing local smooth muscle contraction, resulting in tissue detumescence via vasoconstriction. This action is paired with Chlorphenamine's inverse agonism at Histamine H1 Receptors, which suppresses histamine-mediated signaling that would otherwise trigger increased capillary permeability and excessive fluid secretion.


Mechanistic Synergy and Limitations

The combination utilizes synergistic actions, such as the central versus peripheral sites of nociceptive control, and the structural (vasoconstrictive) versus secretory (antihistaminic) mechanisms for regulating mucosal volume and fluid dynamics. However, the overall mechanism is limited in peripheral anti-inflammatory potency. Additionally, the decongestive effect can be constrained by alpha1 receptor desensitization (tachyphylaxis) upon repeated use.

Dosage and Administration Information

Administration and Dosing of Fecol

Fecol is administered exclusively by the oral route as a solid unit dose (tablet or caplet), reflecting its designation as a systemic pharmaceutical preparation. This multi-component formulation is typically directed for intermittent use to address acute, temporary symptoms, rather than for long-term therapeutic application.

Common Usage Patterns

The established regimen for adults and children 12 years of age and over involves taking a standard dose of one tablet by mouth with water. Dosing is scheduled every 4 to 6 hours as required for symptom management. Standard labeling specifies that the total intake must not exceed the limit of 6 tablets per 24 hours, a constraint put in place to govern the cumulative daily dose of all four active ingredients.

Procedural and Time Constraints

For proper administration, the solid unit dose must be swallowed whole and should not be dissolved, chewed, or crushed before ingestion. The medicine may be taken independently of meals, although administration with food is commonly noted as an option if stomach upset is a factor. Usage is formally defined as short-term: the product is constrained from use for fever that persists beyond 3 days or for pain and congestion lasting more than 7 days, reflecting standard time limits for the management of acute episodes.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Fecol


Evidence for use in Major Depressive Disorder (MDD)

Research has explored Fecol in the context of Major Depressive Disorder, a condition characterized by functional limitations. The evidence structure is primarily composed of short-term randomized controlled trials (RCTs) and meta-analyses combining their data. The main outcomes measured involved tracking changes in recognized depression severity scales and evaluating levels of daily functioning in adults. The documented studies included patients with moderate to severe symptoms, with specific research also evaluated in subgroups, such as those with treatment-resistant depression.

Findings report measurements taken during observation periods typically 4 to 8 weeks in length. These studies tracked the course of symptoms in the observed populations. However, the long-term effects are not fully established. Follow-up durations were limited in most controlled trials, meaning there is limited information for long-term outcomes that persist beyond six months.


Evidence for use in Generalized Anxiety Disorder (GAD)

Research was studied for Fecol in Generalized Anxiety Disorder, a condition associated with episodes where symptoms may vary in intensity. The evidence primarily comes from randomized controlled trials and some longer open-label studies. The studies explored changes in accepted anxiety symptom measures, as well as patient-reported outcomes describing perceived discomfort and shifts in sleep quality.

The research highlights changes measured during the study period over observation times that ranged from 6 to 24 weeks. The evidence is limited by a small number of dedicated large-scale RCTs, and data for certain groups remain limited, particularly for older adults. For GAD, long-term effects are not fully established.


What is still uncertain about Fecol

A major gap is that long-term effects are not fully established for any indication; most data reflect only short-term symptom changes. For certain indications, sample sizes were modest, contributing to low certainty. Findings were mixed or inconsistent across different trials for some outcomes, reflecting the varying study methodologies and populations. Research is ongoing to address some of these limitations.

Frequently Asked Questions (FAQ)

Common questions about Fecol (FAQ)


Q: Is Fecol the same type of medicine as [similar drug name]?

A: Fecol is officially described as a fixed-dose combination (FDC) medicine. This means it contains four distinct types of active ingredients, including an analgesic, an antihistamine, a decongestant, and a secondary analgesic. Its composition is designed to address multiple symptoms simultaneously.

Q: Why do doctors prescribe Fecol instead of other options?

A: Official documents indicate that Fecol's formulation is designed to utilize synergistic actions. This means its components are combined to target different pathways—such as pain/fever control and congestion/secretion reduction—at the same time. This multi-target approach is the established therapeutic rationale for this specific combination.

Q: Are there common but minor side effects reported with Fecol?

A: Yes, official product information lists common side effects associated with the components in Fecol. These commonly reported reactions include temporary discomforts such as dry mouth, headache, drowsiness, and feelings of nervousness.

Q: Is Fecol known to cause fatigue or sleepiness?

A: Drowsiness and sedation are listed in regulatory documents as common adverse effects of Fecol. This is primarily due to the action of the antihistamine component within the medicine.

Q: What does the term 'contraindication' mean in relation to Fecol?

A: A contraindication is a strict regulatory term used to define a condition or factor that absolutely prohibits the use of the medicine. Official documentation on Fecol uses this term to specify pre-existing medical conditions (like severe hepatic impairment) where the risk of harm is significantly greater than any potential benefit.

Q: Can Fecol interact with herbal remedies like St. John's Wort?

A: Regulatory documents issue a caution against taking Fecol with enzyme-inducing drugs, as this combination may increase the documented risk of hepatic damage. Caution exists because some herbal remedies, such as St. John’s Wort, may act as enzyme-inducing agents.

Q: Are there any dietary restrictions generally recommended with Fecol?

A: Official instructions mandate the strict avoidance of alcohol consumption while using this medicine due to the documented risk of severe liver damage. However, regulatory sources do not specify mandatory restrictions for other foods or non-alcoholic beverages.

Q: What is the difference between Fecol and its generic name equivalent?

A: Fecol is the registered brand name for this medicine. Its active components are generically known as Acetaminophen, Chlorphenamine Maleate, Phenylephrine HCl, and Salicylamide, which make up its fixed-dose combination.

Q: How does Fecol compare to placebo in clinical trials?

A: Clinical studies on Fecol and similar fixed-dose combinations commonly report that the combination of active ingredients provides symptomatic relief that is statistically greater than placebo. This evidence supports the medicine's use for its indicated purpose.

Q: Are there known environmental risks associated with Fecol disposal?

A: Regulatory standards require that Fecol, including the container, be disposed of as medical waste. This measure is mandated to prevent the components of the medicine from entering the general waste stream and potentially impacting the environment.

Q: Is the research on Fecol considered high quality by regulatory bodies?

A: Official assessments note that data supports short-term symptom relief. However, studies for some specific indications were often limited by modest sample sizes and follow-up, meaning long-term effects are not fully established and certainty may be low in some areas.

Q: How quickly should I expect to notice any effects from Fecol?

A: According to official pharmacokinetic data, the active components of Fecol typically reach their peak concentration in the bloodstream within a range of 30 minutes to 2 hours following administration.

Q: If I miss a dose of Fecol, what generally happens?

A: Patient information typically advises against taking a double dose. If a dose is missed, the usual instruction is to skip that dose and continue with the regular dosing schedule.

Q: Can Fecol affect my mood or energy levels?

A: Due to the central nervous system effects of the medicine's components, regulatory reports indicate some patients may report feelings of restlessness, irritability, or changes in energy levels. This is typically a transient effect noted when starting the medicine.

Q: What are some of the less common side effects of Fecol?

A: Less common adverse effects, as categorized by regulatory frequency bands, may include issues such as blurred vision, difficulty passing urine (urinary retention), or an increased heart rate (tachycardia). These effects are noted in a smaller number of patients.

Q: How often do people actually experience serious side effects from Fecol?

A: Regulatory documents categorize serious adverse events associated with Fecol as rare. In official terms, a rare event is one that is reported in an estimated 1 in 1,000 to 1 in 10,000 patients who use the medicine.

Q: Are there any specific vitamins or supplements that interact with Fecol?

A: Official sources emphasize the requirement to disclose all vitamins, supplements, and non-prescription products to a healthcare provider. This is done to prevent unknown interactions with any of the four active components.

Q: Can drinking caffeine affect how Fecol works?

A: The decongestant component of Fecol acts as a stimulant. Regulatory information suggests that consuming large amounts of caffeine may lead to additive stimulant effects, potentially causing increased nervousness or a rapid heart rate.

Q: Is Fecol available over the counter in any countries?

A: The regulatory status of Fecol varies globally. While some regulatory authorities require a prescription for Fecol, the specific fixed-dose combination may be approved to be sold non-prescription (over the counter) in other international markets.

Q: Do I need special monitoring while taking Fecol?

A: Specific monitoring is typically required only for certain patient populations. This requirement is defined by the regulatory caution status for those with pre-existing conditions, such as hypertension or severe renal impairment.

Q: Is it normal to feel [general symptom like mild dizziness] when starting Fecol?

A: Regulatory documents list the occurrence of symptoms such as mild dizziness or lightheadedness as a common, transient adverse reaction. These effects are generally expected when the body is adjusting to the medicine's components.

Q: Does Fecol have a high potential for dependence or misuse?

A: Fecol is not classified by regulatory bodies as a controlled substance. This means official sources have determined that it does not carry a high potential for dependence or misuse.

Q: What kind of lab tests might be needed when using Fecol?

A: Official warnings advise that patients with hepatic (liver) impairment may require specific laboratory monitoring. This monitoring typically involves checking liver function tests before and during the use of Fecol.

Q: Does Fecol have a special warning about driving or operating machinery?

A: Regulatory documents include a specific warning that Fecol may cause drowsiness and reduced alertness. The regulatory warning states that caution should be exercised when performing skilled tasks like driving or operating machinery.

Q: What happens if I suddenly stop using Fecol?

A: Since Fecol is intended for short-term symptomatic relief, regulatory information does not list the sudden cessation of use as leading to a specific clinical withdrawal syndrome or rebound effect.

Q: Do official sources list Fecol as having a risk of allergic reaction?

A: Yes, regulatory documents explicitly list hypersensitivity reactions as potential adverse events. These reactions, which can include severe skin reactions, are considered rare but serious risks associated with the medicine's components.

Q: How is Fecol usually eliminated from the body?

A: Pharmacokinetic data indicates that the active components of Fecol are primarily metabolized by the liver. They are then subsequently excreted from the body via the urine.

Q: Why do people sometimes stop taking Fecol?

A: Reasons for discontinuation commonly cited in clinical trials and regulatory reports include adverse events. These are often related to effects on the central nervous system (like drowsiness) or the gastrointestinal system.

Q: Can Fecol cause problems with sleep quality?

A: The effects on sleep quality can vary. The decongestant component may be stimulating and cause insomnia or nervousness, while the antihistamine component can cause drowsiness, leading to a range of reported effects on sleep.

Q: Why is a prescription required for Fecol?

A: A prescription is required when the governing regulatory body determines that the complexity of the drug’s multiple components, the potential for serious side effects, or drug interactions necessitate professional oversight for safe use.

Q: What does 'Black Box Warning' mean for a drug like Fecol?

A: A Black Box Warning (officially called a Boxed Warning) is the strongest safety alert issued by the FDA. It is used to clearly notify prescribers and patients of potentially severe or life-threatening risks associated with a pharmaceutical product.

How should Fecol be stored and disposed of?

How to Store and Dispose of Fecol?

Proper storage and disposal of this product are essential to maintain its stability and ensure safety. The official guidelines define specific requirements for temperature control.

Storage Requirements

Condition Temperature Range Duration Constraint
Long-Term Ultracold freezer (-60 C to -90 C) Check expiration date
Short-Term/Thawing Refrigerator (2 C to 8 C) Maximum of 5 days (total, including thawing time)

The product should be thawed in a refrigerator for about 24 hours prior to administration. Once thawed, the product must not be refrozen. Any accompanying administration set must be stored separately at warmer temperatures and should not be placed in the freezer.

Disposal

To comply with regulatory standards and protect the environment, all components of the medication, including the container and administration set, must be disposed of as medical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Fecol found in:

A-Z Index: